Ikaria Files for $200 Million IPO

Ikaria, a Clinton, N.J.-based biopharma company, has filed for a $200 million IPO. It plans to trade on the Nasdaq under ticker symbol IKAR, with Goldman Sachs and Morgan Stanley serving as co-lead underwriters.

The company reports nearly $275 million in 2009 revenue, compared to $237 million last year. Its net income grew from $9.6 million to $13 million.

Ikaria shareholders include New Mountain Capital (50.98% pre-IPO position), Linde (17.1%), ARCH Venture Partners (10.13%), Venrock (10.1%), 5AM Ventures, Alexandria Equities, Altitude Life Science Ventures and Washington Research Foundation. New Mountain and Linde joined in 2007, when New Mountain invested $200 million to fund Ikaria’s $670 million acquisition of gaseous drugmaker INO Therapeutics from Linde. www.ikariainc.com